CARL ZEISS MEDITEC ADR 1 Capital Reinvestment Ratio
CARL ZEISS MEDITEC ADR 1 capital reinvestment ratio. CARL ZEISS MEDITEC ADR 1 (AFXA) has a Capital Reinvestment Ratio of 0.36x as of September 2025, meaning it reinvests 0% of its operating cash flow (€209.86 Million) in capital expenditures (€76.59 Million). See CARL ZEISS MEDITEC ADR 1 free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of CARL ZEISS MEDITEC ADR 1 (2022–2025)
Capital reinvestment ratio of CARL ZEISS MEDITEC ADR 1 from 2022 to 2025. This chart tracks CARL ZEISS MEDITEC ADR 1's Capital Reinvestment Ratio across 4 annual periods. See AFXA financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CARL ZEISS MEDITEC ADR 1 Capital Reinvestment Ratio by Year (2022–2025)
CARL ZEISS MEDITEC ADR 1 capital reinvestment ratio by year from 2022 to 2025. For the full cash flow conversion analysis, see CARL ZEISS MEDITEC ADR 1 (AFXA) cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.36x | €209.86 Million | €76.59 Million | ▼ -40.7% |
| 2024 | 0.62x | €247.32 Million | €152.20 Million | ▲ +35.6% |
| 2023 | 0.45x | €250.86 Million | €113.86 Million | ▲ +4.2% |
| 2022 | 0.44x | €188.20 Million | €81.97 Million | — |